Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.217 | Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus | Prof. MOK Tony S. K. |
| 2008.229 | A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, As Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer | Professor Mok Tony S. K. |
| 2009.274 | A Phase III, multi-center, placebo-controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens | Prof. Mok Tony S. K. |
| 2009.638 | Phase 2, Open-label, Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus | Prof. MOK Tony S. K. |
| 2014.487 | A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) | Prof. MOK Tony S. K. |
| 2014.356 | A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3) | Prof. MOK Tony |
| 2010.228 | Mapping of activating and resistant EGFR mutations in pulmonary adenocarcinoma | Professor Mok Tony |
| 2013.021 | A Survey of the Current Status of EGFR Mutation Testing in Asia | Prof. Mok Tony |
| 2008.248 | A Randomized, Multicenter Phase II Study to Explore Whether Biomarkers Correlate with Treatment Outcome in Chemo-Na・e Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer, Who Receive Treatment with Bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in Addition to Carboplatin-based Chemotherapy (Gemcitabine or Paclitaxel) | Professor Mok Tony |
| 2007.445 | Phase II Study of AZD 2171 in Patients with Recurrent Small Cell Lung Cancer | Professor Mok Tony |
| 2011.602 | A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM. IMPRESS- (IRESSATM Mutation Positive Multicentre Treatment Beyond ProgRESsion Study) | Prof. MOK Tony |
| 2014.257 | A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive (AURA2) | Prof. MOK Tony |
| 2009.248 | A randomized phase II study comparing acupuncture to acupuncture with moxibustion on reduction of chemotherapy-induced neutropenia | Professor Mok Tony |
| 2009.595 | A Phase 1B/2 Study of SCH 900105 in Combination with Gefitinib in Asian Subjects with Non-Small Cell Lung Cancer | Professor Mok Tony |
| 2008.056 | Phase IIb/III Randomized, Double-Blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | Professor Mok Tony |
| 2009.010 | A Phase II Study to Evaluate the Effectiveness of Acupuncture in Treating Chemotherapy Induced Peripheral Neuropathy (CIPN) | Professor Mok Tony |
| 2008.583 | A randomised, placebo-controlled, double-blind phase III study of intercalated Tarceva_ (erlotinib) or placebo with gemcitabine/platinum as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) | Prof. MOK Tony |
| 2009.331 | Clinical Application of Epidermal Growth Factor Receptor (EGFR) Mutation as Predictive Biomarker for EGFR Tyrosine Kinase Inhibitor (TKI) in Never/Light-Smoker with Adenocarcinoma of Lung | Prof. MOK Tony |
| 2011.396 | A Randomized Double Blind Phase 3 Efficacy And Safety Study Of PF-00299804 Versus Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy | Prof. MOK Tony |
| 2009.392 | LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation | Prof. MOK Tony |
| 2020.025 | A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations |
Prof. MOK Tony 莫樹錦教授 |
| 2018.394 | The Circulating Cell-free Genome Atlas in Asia (CCGAsia) Study |
Prof. MOK Tony 莫樹錦教授 |
| 2018.434 | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer |
Prof. MOK Tony 莫樹錦教授 |
| 2005.209 | The Health-Related Quality of Life of Chronic Hepatits B Carriers in Hong Kong | MOK Suet Yuk |
| 2016.229 | Stereotactic Radiosurgery (SRS)/ Radiotherapy (SRT) for Brain Metastases: A Review of Outcomes and Prognostic Scores Evaluation |
Dr Mok SIU TING 莫小婷 |
| 2020.341 | To determine the clinical effect of Local ablative radiotherapy such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) on various metastatic cancers | Dr. MOK Siu Ting |
| 2012.225 | A Randomized, Phase III, Multicenter, Double Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination With Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) who have Received Standard Chemotherapy for Advanced or Metastatic Disease | Prof. Mok Shu-Kam |
| 2022.334 | HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy |
Prof. MOK Shu Kam 莫樹錦教授 |
| 2013.448 | Streamlining workflow by using water instead of iodinated oral contrast for CT Abdomen & Pelvis | Ms. MOK Serena Sum Yee |
| 2010.083 | High Performance Multi-pinhole SPECT for Clinical and Preclinical Molecular Imaging | Dr Mok Seng Peng, Greta |
| 2013.645 | Clinical siginificance and functional effects of NCOA2 in colorectal cancer | Dr Mok Myth Tsz Shun |
| 2017.028 | Relationship between knee kinematics and functional performance during an isometric single-leg squat |
Dr. MOK Kam Ming 莫鑑明 |
| 2011.232 | Sleep Disturbance in Chinese Palliative Care Patients and Its Impact on Quality of Life | Dr Mok Ka Wai Alice |
| 2020.472 | Retrospective Cohort Study of Lung Cancer in Hong Kong |
Dr. MOK Florence Siu Ting MOK 唐美思 |
| 2020.463 | Outcomes and hearing loss after definitive Intensity Modulated Radiotherapy (IMRT) in Nasopharyngeal carcinoma: Dose effect and toxicity relationship |
Dr. MOK Florence Siu Ting 莫小婷 |
| 2014.477 | Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) | Dr. MOK Florence Siu Ting |
| 2024.700 | Comparing efficacy of oral azithromycin versus topical azithromycin in the treatment of meibomian gland dysfunction using in vivo confocal microscopy | Dr. MOK Eugenie |
| 2020.394 | Corneal Nerve Changes in Herpes Zoster Ophthalmicus |
Dr. MOK Eugenie 莫曉瑜 |
| 2009.497 | Follow-up of a randomized clinical trial ("ViNeuro"): Incidence of Cognitive decline and dementia in Chinese Parkinson's disease patients | Prof Mok Chung Tong, Vincent |
| 2007.454 | Occupational and Parkinson's Disease in Hong Kong - A Case-Control Study | Prof. MOK Chung Tong, Vincent |
| 2008.319 | Effect of LY450139, A | Dr MOK Chung Tong, Vincent |
| 2009.593 | A 78-Week Noninterventional Longitudinal Study to Validate the Alzheimer | Prof. Mok Chung Tong Vincent |
| 2007.502 | Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer | Professor Mok Chung Tong Vincent |
| 2014.221 | Pilot study on Microelectronic Neural Bridge in improving rehabilitation outcome for stroke patients with upper limb paresis | Professor MOK chung tong Vincent |
| 2017.612 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD) |
Prof. MOK Chung Tong 莫仲棠 |
| 2016.355 | Burnout among physician engaged in palliative care in Hong Kong public hospitals -- BUPPALHO study | Dr. MOK Alice Ka Wai |
| 2020.099 | Hong Kong Real-World Data Analytics and Genomic-Guided Therapy Research Project | Dr. MOK Florence Siu Ting |
| 2025.510 | Accuracy of magnetic resonance imaging in diagnosing leptomeningeal metastasis from lung carcinoma – a 10-year retrospective analysis in a tertiary referral hospital |
Dr. MO Tsun Ming 毛浚銘 |
| 2013.043 | Effectiveness of an Integrated Social Skills Training (ISST) with Social Cognition Component for people with Schizophrenia: A Clinical Control Trial | Ms Mo Sung Yu, Chloe |
| 2014.347 | A randomised controlled trial evaluating efficacy of a psychological intervention based on Commonsense Model in improving mental health and self-care among Type-2 Diabetes Mellitus patients | Prof. MO Phoenix Kit Han |
Page 95 of 268.